Manifaxine

Source: Wikipedia, the free encyclopedia.
Manifaxine
Clinical data
Other namesGW-320,659
Routes of
administration		Oral
ATC code
  • none
Identifiers
  • (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
JSmol)
  • C[C@@H]1CO[C@]([C@@H](N1)C)(C2=CC(=CC(=C2)F)F)O
  • InChI=1S/C12H15F2NO2/c1-7-6-17-12(16,8(2)15-7)9-3-10(13)5-11(14)4-9/h3-5,7-8,15-16H,6H2,1-2H3/t7-,8+,12-/m1/s1 ☒N
  • Key:OZGPVYJHWWPEFT-RGNHYFCHSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Manifaxine (developmental code name GW-320,659) is a

structural modification of radafaxine, an isomer of hydroxybupropion and one of the active metabolites of bupropion.[1] Manifaxine was researched for treatment of attention deficit hyperactivity disorder (ADHD) and obesity and was found to be safe, reasonably effective, and well-tolerated for both applications.[2][3] However, no results were reported following these initial trials and development was discontinued.[1]

Synthesis

Synthesis:[4] Patent:[5] See also:[6][7]

The Grignard reaction between 3,5-difluorobenzonitrile [64248-63-1] (1) and ethylmagnesium bromide gives 3,5-difluoropropiophenone [135306-45-5] (2). Halogenation with molecular bromine occurs at the alpha-keto position providing 2-bromo-3',5'-difluoropropiophenone [135306-46-6] (3). Intermolecular ring formation with DL-Alaninol (2-Aminopropanol) [6168-72-5] completed the synthesis of Manifaxine (4).

See also

References

  1. ^ a b "Manifaxine - AdisInsight".
  2. PMID 12162627
    .
  3. S2CID 40809351
    .
  4. PMID 8558500
    .
  5. ^ James Leroy Kelley, et al. EP0426416 (1991 to Wellcome Foundation Ltd).
  6. ^ Frank Ivy Carroll, et al. US9562001 (2012 to Research Triangle Institute).
  7. ^ Frank Ivy Carroll, et al. US20180215701 (Research Triangle Institute).



drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Manifaxine&oldid=1190969643"